COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world ...

They are more likely to die from disease. They are more likely to die from violence. They are more likely to die as they age. And they don’t live nearly as long. The life expectancy of people with ...

A new study has identified specific genetic variants that confer a high risk for developing schizophrenia and other mental ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...

Researchers at the University of Seville have identified the possible origins of structural damage in the brains of patients with schizophrenia spectrum disorders (SSDs). These are regions that show ...

The Schizophrenia & Psychosis Action Alliance recently welcomed five new members to its Board of Directors. Port Washington resident Donna Taylor is one of the recently appointed board members. The ...

Check out these resources for more information about childhood schizophrenia. March 12, 2010— -- For almost eight months, "20/20" chronicled the lives of three families with kids that have ...

Symptoms of schizophrenia, a serious mental disorder that can include hallucinations and delusions, vary greatly from person to person. One common group of schizophrenia symptoms that doesn’t always ...